Ascentage Pharma Group International

AAPG · NASDAQ

Official-source baseline for Ascentage Pharma using SEC submissions, FY2025 Form 20-F, SEC companyfacts, company-filed FY2025 results releases, ASCO 2026 update, annual meeting materials, and oncology peer filings.

Follow Add to Watchlist Ask Question

NASDAQ AAPG Coverage Bootstrap Biotechnology Oncology China Healthcare

Latest ReportMay 13, 2026Ascentage Pharma (AAPG) Coverage Bootstrap: commercial-stage oncology biotech with China approvals and global Phase 3 optionalityView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

BiotechnologyOncology

Clear tags

MatchAny tag All tags

Latest Thesis

Ascentage Pharma (AAPG) Coverage Bootstrap: commercial-stage oncology biotech with China approvals and global Phase 3 optionality

May 13, 2026Research reportSlides available

Read report Open slides Discussion (0)

Ascentage Pharma Group InternationalPharma (AAPG) Coverage Bootstrap: commercial-stage oncology biotMay 13, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

Ascentage Pharma (AAPG) Coverage Bootstrap: commercial-stage oncology biotech with China approvals and global Phase 3 optionalityOfficial-source baseline for Ascentage Pharma using SEC submissions, FY2025 Form 20-F, SEC companyfacts, company-filed FY2025 results releases, ASCO 2026 update, annual meeting materials, and oncology peer filings.NASDAQMay 13, 2026Research reportRead Slides